Literature DB >> 9862685

Induction or protection from experimental autoimmune encephalomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4 T cells.

V Kumar1, E Sercarz.   

Abstract

Autoimmune diseases can result from the breakdown of regulation and subsequent activation of self-antigenic determinant-reactive T cells. During the evolution of the autoimmune response to myelin basic protein (MBP) in B10.PL mice, several distinct T cell populations expand: the effectors mediating experimental autoimmune encephalomyelitis (EAE) are MBP-reactive, CD4+, and predominantly TCR Vbeta8.2+; in addition, at least two regulatory populations can be detected--one comprised of Vbeta14+ CD4 T cells, reactive to a framework region 3 determinant on the Vbeta8.2 chain, and a second that is CD8+ and reactive to another Vbeta8.2 determinant. The combined action of these two regulatory cell types controls disease-causing effectors, resulting in spontaneous recovery from disease. In this report, we reveal that the cytokine secretion pattern of TCR peptide-specific regulatory CD4 T cells can profoundly influence whether a type 1 or type 2 population predominates among MBP-specific CD4 effectors. The priming of type 1 regulatory T cells results in deviation of the Ag-specific effector T cell population in a type 2 direction and protection from disease. In contrast, induction of type 2 regulatory T cells results in exacerbation of EAE, poor recovery, and an increased frequency of type 1 effectors. Thus, the encephalitogenic potential of the MBP-reactive effector population is crucially and dominantly influenced by the cytokine secretion phenotype of regulatory CD4 T cells. These findings have important implications in understanding peripheral tolerance to self-Ags as well as in the design of TCR-based therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862685

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Homeostatic control of immunity by TCR peptide-specific Tregs.

Authors:  Vipin Kumar
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  Immunopathogenesis of dilated cardiomyopathy. Evidence for the role of TH2-type CD4+T lymphocytes and association with myocardial HLA-DR expression.

Authors:  Friedhelm Kuethe; Ruedi K Braun; Martin Foerster; Yvonne Schlenker; Holger H Sigusch; Claus Kroegel; Hans R Figulla
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

4.  Global expression profiling of peripheral Qa-1-restricted CD8αα+TCRαβ+ regulatory T cells reveals innate-like features: implications for immune-regulatory repertoire.

Authors:  Shaohsuan S Fanchiang; Radu Cojocaru; Mohammad Othman; Ritu Khanna; Matthew J Brooks; Trevor Smith; Xiaolei Tang; Igor Maricic; Anand Swaroop; Vipin Kumar
Journal:  Hum Immunol       Date:  2011-08-17       Impact factor: 2.850

5.  Cytokine expression and synovial pathology in the initiation and spontaneous resolution phases of adjuvant arthritis: interleukin-17 expression is upregulated in early disease.

Authors:  K A Bush; J S Walker; C S Lee; B W Kirkham
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

6.  IFNγ influences type I interferon response and susceptibility to Theiler's virus-induced demyelinating disease.

Authors:  Jenna L Bowen; Julie K Olson
Journal:  Viral Immunol       Date:  2013-07-05       Impact factor: 2.257

7.  Loss of β-arrestin 2 exacerbates experimental autoimmune encephalomyelitis with reduced number of Foxp3+ CD4+ regulatory T cells.

Authors:  Yu Zhang; Chang Liu; Bin Wei; Gang Pei
Journal:  Immunology       Date:  2013-12       Impact factor: 7.397

8.  Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis.

Authors:  Florence Jambou; Wei Zhang; Monique Menestrier; Isabelle Klingel-Schmitt; Olivier Michel; Sophie Caillat-Zucman; Abderrahim Aissaoui; Ludovic Landemarre; Sonia Berrih-Aknin; Sylvia Cohen-Kaminsky
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 9.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 10.  Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment.

Authors:  Paula E Goines; Paul Ashwood
Journal:  Neurotoxicol Teratol       Date:  2012-08-17       Impact factor: 3.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.